Our pioneering approach uses systematic gene editing, in vivo imaging and deep learning-based image analysis to comprehensively discover and validate targets for theraputic intervention.
Veyviser was founded in 2021 from the idea to maximise the clinical potential of zebrafish larvae and make it accessible to a larger market, to light the path towards prevention and treatment of diseases.
